|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
20 June 2022 |
|
Main ID: |
ChiCTR-OOC-17012524 |
|
Date of registration:
|
2017-09-01 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Research of molecular basis of delayed asexual parasite clearance times in treatment of Plasmodium falciparum malaria with dihydroartemisinin-piperaquine in Yunnan and neighboring areas of other countries
|
|
Scientific title:
|
Research of molecular basis of delayed asexual parasite clearance times in treatment of Plasmodium falciparum malaria with dihydroartemisinin-piperaquine in Yunnan and neighboring areas of other countries |
|
Date of first enrolment:
|
2017-10-01 |
|
Target sample size:
|
Group of DHA-PPQ sensitivity surveillance:100; |
|
Recruitment status: |
Pending |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=21339 |
|
Study type:
|
Observational study |
|
Study design:
|
Single arm
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Myanmar
| | | | | | | |
|
Contacts
|
|
Name:
|
Jian-wei XU
|
|
Address:
|
6 Xiyuan Road, Simao District, Puer, Yunnan, China
665000
|
|
Telephone:
|
+86 18987921137 |
|
Email:
|
xjw426@163.com |
|
Affiliation:
|
Yunnan Institute of Parasitic Diseases |
|
|
Name:
|
Hui LIU
|
|
Address:
|
6 Xiyuan Road, Simao District, Puer, Yunnan, China
665000
|
|
Telephone:
|
+86 15308796079 |
|
Email:
|
liubible@126.com |
|
Affiliation:
|
Yunnan Institute of Parasitic Diseases |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Microscopy- confirmed patients with monoinfections of P. falciparum;
2. Aged 1–65 years;
3. Asexual parasite density =500 parasites/ul.
Exclusion criteria: 1. Pregnancy;
2. Having taken any anti-malarial drug within the past 14 days;
3. History of hypersensitivity to any of the study drugs;
4. Severe dysfunction of kidney, liver and heart;
5. Severe malaria such as cerebral malaria, hyper body temperature (>41 degree C);
6. Unable to follow up.
Age minimum:
1
Age maximum:
65
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
malaria
|
|
Intervention(s)
|
|
Group of DHA-PPQ sensitivity surveillance:DHA-PPQ;
|
|
Primary Outcome(s)
|
|
Parasite clearance times;Fever clearance times;ring-stage survival rate;
|
|
Source(s) of Monetary Support
|
|
National Nature Science Foundation of China
|
|
Ethics review
|
Status: Approved
Approval date: 14/03/2016
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|